Ajinkya Kulkarni, MD
Medical Oncology · Dover, DENPI 1962997668
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,432 of the $1,601 with a category attached, or 89.4%. It is spread thinly across 17 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 47 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$298
- AstraZeneca$284
- Eisai Inc.$153
- Beigene USA, Inc.$125
- Bristol Myers Squibb$124
- Genmab U.S., Inc.$90
- plus $528 from 11 others
What the payments were for
- Food & beverage$1,43289%
- Education$16911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 14 | $298 |
| AstraZeneca(2 entities) | 3 | $284 |
| Eisai Inc. | 7 | $153 |
| Beigene USA, Inc. | 1 | $125 |
| Bristol Myers Squibb | 2 | $124 |
| Genmab U.S., Inc. | 3 | $90 |
| Seagen Inc. | 1 | $86 |
| Astellas Pharma US Inc | 1 | $83 |
| Sanofi | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Merck | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Gilead | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $29 |
| Myovant Sciences Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Promethazine Hcl | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dover
- Rishi SawhneyDover$11K
- Mohamad GhraowiDover$461
- Madhulika UrellaDover$443
- Gerard KennealeyWilmington$88K
- Michael GuarinoNewark$3K
- Lydia ClementsNewark$1K
- Gregory MastersNewark$1K
- Susan SchafferNewark$593
- Victor SandorWilmington$301
- Stephen GrubbsNewark$129
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.